You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023240020
Dec 202330011
Jan 20245905
Feb 20243602
Mar 20244406
Apr 20243801
May 20243000
Jun 20243000
Jul 20243401
Aug 20245401
Sep 20243602
Oct 20243203
Nov 20245608
Dec 20241805
Jan 20253006
Feb 20251402
Mar 2025001
Apr 2025007
May 2025102
Jun 2025202
Total784085